Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

The coronavirus pandemic is throwing a spotlight on stocks in the U.S. health-care sector, home to the companies that could develop treatments, vaccines and improved diagnostics needed to tackle the greatest public-health crisis in a century.

Health care has held up better than most S&P 500 sectors. Since the S&P 500 hit a record high on Feb. 19, health-care stocks are down about 18 per cent as of Wednesday, while the benchmark index has tumbled 27 per cent.

The sector is typically considered a defensive area of the market because some investors believe consumers will continue buying health-care products even during uncertain times.

Story continues below advertisement

Shares of pharmaceutical and biotechnology companies have led the pack, including those working on potential treatments and other ways to address the rapidly spreading COVID-19 pandemic.

In particular, shares of Regeneron Pharmaceuticals Inc. and Gilead Sciences Inc. have risen 24 per cent and 8 per cent, respectively, since the S&P hit its peak.

“A lot of these companies are working on a solution to the problem,” said Walter Todd, chief investment officer with Greenwood Capital in South Carolina. “We can debate what it means to them … monetarily, but perception-wise they are viewed as a safe haven because of that.”

Greenwood Capital in recent weeks bought shares of Regeneron and Roche Holding AG, a Swiss company that has diagnostics and a potential therapy for the new coronavirus.

The purchases added to the firm’s overweight position in the health-care sector, although it has pared its holdings during the recent outperformance, Mr. Todd said.

Health care lagged the market’s big gains in 2019. Institutional investors generally held a lower weighting in the sector relative to benchmark indexes before the pandemic took hold this year, said Rebecca Chesworth, senior equities strategist at State Street Global Advisors.

Health care “has been one of the most popular places to put money in the past couple of weeks,” she added.

Story continues below advertisement

The sector recently traded at 12.9 times forward 12-month earnings estimates, compared with 14 times for the overall S&P 500, according to Refinitiv Datastream.

Pharmaceutical and biotech stocks, including Eli Lilly and Co. and Vertex Pharmaceuticals Inc., make up eight of the sector’s 10 best performers since Feb. 19, all of which have gained or fallen far less than the broader market.

“In general, if you are on a drug, you are staying on that drug,” said Teresa McRoberts, a portfolio manager who focuses on health care at Fred Alger Management. “So that part of their business is pretty safe.”

Some areas of the sector have been hit hard by the vast ripple effects of the virus, particularly medical-device companies dependent on elective procedures that are being delayed to preserve hospital capacity and resources for coronavirus patients. Shares of Zimmer Biomet Holdings and Stryker Corp., which are in the knee- and hip-replacement fields, are down 44 per cent and 36 per cent, respectively, since Feb 19.

Shares of hospital chain HCA Healthcare Inc. have slumped 44 per cent over that period as hospitals lose high-margin elective procedures and cope with severe disruption from the influx of coronavirus patients, said Jeff Jonas, health-care portfolio manager with Gabelli Funds.

Mr. Jonas, however, says those areas could be quicker to recover than other parts of the economy when the pandemic recedes.

Story continues below advertisement

“You’re going to be more nervous about getting on a plane, staying in a hotel, going out to dinner in the aftermath of this than you are about going back to see your doctor or to get a procedure done,” he said.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies